EUVIMEDEUVIMED entdecken
Crossref

Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods

Lei Yan, Ziji Yu, Liwen Wu, Rachael Liu, Jianchang Lin

Therapeutic Innovation & Regulatory Science · 2025-05 · 59 (3) · 566-578

DOI: 10.1007/s43441-025-00754-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 25.02.2025. Verfasst von Lei Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, Florida State University, Tallahassee, FL, USA. Hauptthemen laut MEDLINE: Machine Learning, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The traditional clinical trial monitoring process, which relies heavily on site visits and manual review of accumulative patient data reported through Electronic Data Capture system, is time-consuming and resource-intensive. The recently emerged risk-based monitoring (RBM) and quality tolerance limit (QTL) framework offers a more efficient alternative solution to traditional SDV (source data verification) based quality assurance. These frameworks aim at proactively identifying systematic issues that impact patient safety and data integrity. In this paper, we proposed a machine learning enabled approach to facilitate real-time, automated monitoring of clinical trial QTL risk assessment. Unlike the traditional quality assurance process, where QTLs are evaluated based on single-source data and arbitrary defined fixed threshold, we utilize the QTL-ML framework to integrate information from multiple clinical domains to predict the QTL of variety types at clinical program, study, site and patient level. Moreover, our approach is assumption-free, relying not on historical expectations but on dynamically accumulating trial data to predict quality tolerance limit risks in an automated manner. Embedded within ICH-E6 recommended RBM principles, this innovative machine learning solution for QTL monitoring has the potential to transform sponsors' ability to protect patient safety, reduce trial duration, and lower trial costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningClinical Trials as TopicHumansRisk Assessment

Stichwörter der Autor:innen

Good clinical practiceMachine learningQuality tolerance limitsRisk-based monitoring

Autor:innen und Institutionen

  • Department of Statistics, Florida State University, Tallahassee, FL, USA.
  • Takeda Pharmaceuticals, Cambridge, MA, USA. ziji.yu@takeda.com.
  • Takeda Pharmaceuticals, Cambridge, MA, USA.

Zitieren

APA

Yan, L., Yu, Z., Wu, L., Liu, R., & Lin, J. (2025). Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods. Therapeutic Innovation & Regulatory Science, 59(3), 566-578. https://doi.org/10.1007/s43441-025-00754-6

Vancouver

Yan L, Yu Z, Wu L, Liu R, Lin J. Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods. Therapeutic Innovation & Regulatory Science. 2025;59(3):566-578. doi:10.1007/s43441-025-00754-6

BibTeX
@article{Yan2025,
  author = {Yan, Lei and Yu, Ziji and Wu, Liwen and Liu, Rachael and Lin, Jianchang},
  title = {Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  volume = {59},
  number = {3},
  pages = {566--578},
  doi = {10.1007/s43441-025-00754-6}
}
Kostenlos starten →